Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
The price-to-book value (P/BV) ratio for the analyzed period exhibits considerable fluctuation, though a general trend towards stabilization can be observed in more recent years. Initially, the ratio demonstrated volatility, followed by a period of relative consistency, and then a renewed period of change. The analysis below details these observations.
- Early Period (2006-2009)
- From 2006 to 2009, the P/BV ratio experienced a decline. Starting at 8.16, it decreased to 2.94. This decrease coincided with a period where the share price experienced both increases and decreases, while book value per share generally increased. The decline suggests that while the company’s net asset value was growing, investor enthusiasm for the stock, relative to that value, diminished during this timeframe.
- Period of Increase (2010-2012)
- Between 2010 and 2012, a significant increase in the P/BV ratio is evident, rising from 5.49 to 19.19. This surge was primarily driven by a substantial increase in the share price, outpacing the growth in book value per share. This indicates a growing investor confidence and willingness to pay a premium for the company’s net assets.
- Fluctuating Values (2013-2018)
- From 2013 through 2018, the P/BV ratio demonstrated more fluctuation, ranging between approximately 8.58 and 16.74. While book value per share continued to increase, the share price experienced periods of both growth and decline, resulting in the observed volatility in the P/BV ratio. The ratio generally decreased from 16.74 to 5.66 during this period.
- Recent Trends (2019-2026)
- The period from 2019 to 2026 shows a more moderate range of P/BV values, generally between 2.62 and 5.07. The ratio initially decreased from 5.07 to 3.60, then increased to 3.96, before decreasing again to 2.62 and finally increasing to 2.67. Book value per share continued its upward trajectory, while the share price experienced more pronounced fluctuations. The most recent values suggest a potential stabilization of the P/BV ratio, though further observation is needed to confirm this trend.
Overall, the P/BV ratio has demonstrated a complex pattern over the analyzed period. The initial decline, followed by a substantial increase, and subsequent fluctuations suggest a dynamic interplay between investor sentiment, share price performance, and the underlying net asset value of the company. The recent trend towards stabilization warrants continued monitoring.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | ||||||||||||
| Feb 5, 2025 | ||||||||||||
| Feb 5, 2024 | ||||||||||||
| Feb 6, 2023 | ||||||||||||
| Feb 7, 2022 | ||||||||||||
| Feb 8, 2021 | ||||||||||||
| Feb 7, 2020 | ||||||||||||
| Feb 7, 2019 | ||||||||||||
| Feb 8, 2018 | ||||||||||||
| Feb 9, 2017 | ||||||||||||
| Feb 11, 2016 | ||||||||||||
| Feb 12, 2015 | ||||||||||||
| Feb 13, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 21, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 18, 2010 | ||||||||||||
| Feb 26, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Mar 12, 2007 | ||||||||||||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/BV, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).